-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IJmVU2+vl2f7++m4UnL5ywwMs4HI9HYOqnMH+wiUV+OR7tQYlS1mBdXMeVbL4ac/ ry/K53bdnYz9ZDYgP3emMg== 0001144204-10-008170.txt : 20100216 0001144204-10-008170.hdr.sgml : 20100215 20100216160613 ACCESSION NUMBER: 0001144204-10-008170 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091231 FILED AS OF DATE: 20100216 DATE AS OF CHANGE: 20100216 EFFECTIVENESS DATE: 20100216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 10607659 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v173996_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2009 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 11, 2009 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 54 ----------- Form 13F Information Table Entry Value: 1,497,934 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 12-31-2009
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acorda Therapeutics COM 00484M106 30,713 1,218,780 SH SOLE 1,218,780 Adolor Corp. COM 00724X102 6,603 4,522,772 SH SOLE 4,522,772 Allos Therapeutics Inc. COM 019777101 33,327 5,064,909 SH SOLE 5,064,909 Alsius Corp. COM 021211107 3 62,872 SH SOLE 62,872 Amicus Therapeutics COM 03152W109 2,571 647,657 SH SOLE 647,657 Amylin Pharmaceuticals COM 032346108 14,867 1,047,700 SH SOLE 1,047,700 Anadys Pharmaceuticals Inc. COM 03252Q408 264 125,023 SH SOLE 125,023 AP Pharma COM 00202J203 8,646 6,861,818 SH SOLE 6,861,818 Aradigm Corp. COM 038505301 14 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 72,052 5,146,589 SH SOLE 5,146,589 Autoimmune Inc. COM 052776101 6 13,050 SH SOLE 13,050 Auxilium COM 05334D107 140,910 4,700,127 SH SOLE 4,700,127 Biocryst Pharmaceuticals Inc. COM 09058V103 35,941 5,563,615 SH SOLE 5,563,615 Cadence Pharmaceuticals COM 12738T100 10,409 1,076,432 SH SOLE 1,076,432 Cephalon Inc. COM 156708109 695 11,140 SH SOLE 11,140 Chelsea Therapeutics COM 163428105 2,420 896,176 SH SOLE 896,176 Cornerstone BioPharma COM 22674T105 685 112,337 SH SOLE 112,337 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 217 92,311 SH SOLE 92,311 Dendreon Corp. COM 24823Q107 23,706 902,069 SH SOLE 902,069 Depomed COM 249908104 614 183,145 SH SOLE 183,145 Genomic Health Inc. COM 37244C101 108,996 5,572,425 SH SOLE 5,572,425 Halozyme Therapeutics Inc. COM 40637H109 11,561 1,969,512 SH SOLE 1,969,512 Human Genome COM 444903108 41,200 1,347,283 SH SOLE 1,347,283 Idera Pharmaceuticals Inc. COM 45168K108 1,069 206,820 SH SOLE 206,820 Incyte Corp. COM 45337C102 120,010 13,173,417 SH SOLE 13,173,417 Infinity Pharmaceuticals Inc. COM 45665G303 862 139,559 SH SOLE 139,559 Inhibitex Inc. COM 45719T103 1,290 1,402,153 SH SOLE 1,402,153 Inspire COM 457733103 19,917 3,608,190 SH SOLE 3,608,190 Inverness Medical COM 46126P106 57,835 1,393,286 SH SOLE 1,393,286 Metabasis Therapeutics Inc. COM 59101M105 764 1,985,603 SH SOLE 1,985,603 Micromet COM 59509C105 20,536 3,083,611 SH SOLE 3,083,611 Neurogen Corp. COM 64124E106 1,497 8,205,406 SH SOLE 8,205,406 Onyx COM 683399109 9,913 337,856 SH SOLE 337,856 Pharmacyclics Inc. COM 716933106 127 40,578 SH SOLE 40,578 Pharmasset Inc. COM 71715N106 1,866 90,147 SH SOLE 90,147 Pharmathene COM 71714G102 635 323,807 SH SOLE 323,807 Salix Pharmaceuticals, Inc. COM 795435106 130,160 5,126,442 SH SOLE 5,126,442 Seattle Genetics Inc. COM 812578102 162,258 15,970,287 SH SOLE 15,970,287 Sucampo CLASS A 864909106 260 64,387 SH SOLE 64,387 Targacept COM 87611R306 14,236 681,148 SH SOLE 681,148 Threshold Pharma COM 885807107 5,535 3,075,391 SH SOLE 3,075,391 Trimeris Inc. COM 896263100 9,068 3,461,175 SH SOLE 3,461,175 Vertex Pharmaceuticals Inc. COM 92532F100 4,285 100,000 SH SOLE 100,000 Via Pharmaceuticals COM 92554T103 21 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 78,916 9,405,977 SH SOLE 9,405,977 Ziopharm Oncology Inc. COM 98973P101 1,909 645,000 SH SOLE 645,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 17,464 18,251,000 PRN SOLE 18,251,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 5,341 5,000,000 PRN SOLE 5,000,000 Cephalon Inc. Notes 2.0% 6/1/2015 CONV BONDS 156708AP4 4,275 3,000,000 PRN SOLE 3,000,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 13,203 6,500,000 PRN SOLE 6,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 208,800 160,000,000 PRN SOLE 160,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 27,620 27,313,000 PRN SOLE 27,313,000 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 17,019 17,500,000 PRN SOLE 17,500,000 Onyx Pharmaceuticals Inc. 4% 8/15/16 CONV BONDS 683399AB5 14,823 14,000,000 PRN SOLE 14,000,000
-----END PRIVACY-ENHANCED MESSAGE-----